{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:13:00Z","timestamp":1791475980226,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T00:00:00Z","timestamp":1485475200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s10067-017-3554-4","type":"journal-article","created":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T06:02:00Z","timestamp":1485496920000},"page":"1341-1348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Metabolite monitoring to guide thiopurine therapy in systemic autoimmune diseases"],"prefix":"10.1007","volume":"36","author":[{"given":"Aur\u00e9lie","family":"Chapdelaine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Troyanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Dor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,27]]},"reference":[{"key":"3554_CR1","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1136\/ard.2010.131995","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau FA, Cruz DD, Sangle S, Remy P, Vasconcelos C, Petrovic R et al (2010) Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis 69:2083\u20132089. doi:\n10.1136\/ard.2010.131995","journal-title":"Ann Rheum Dis"},{"key":"3554_CR2","doi-asserted-by":"publisher","first-page":"e000105","DOI":"10.1136\/lupus-2015-000105","volume":"2","author":"L Croyle","year":"2015","unstructured":"Croyle L, Hoi A, Morand EF (2015) Characteristics of azathioprine use and cessation in a longitudinal lupus cohort. Lupus Sci Med 2:e000105\u2013e000110. doi:\n10.1136\/lupus-2015-000105","journal-title":"Lupus Sci Med"},{"key":"3554_CR3","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","volume":"359","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP et al (2008) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359:2790\u20132803. doi:\n10.1056\/NEJMoa0802311","journal-title":"N Engl J Med"},{"key":"3554_CR4","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, Khouatra C, Auma\u00eetre O, Cohen P et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771\u20131780. doi:\n10.1056\/NEJMoa1404231","journal-title":"N Engl J Med"},{"key":"3554_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1365-2036.2011.04905.x","volume":"35","author":"L Chouchana","year":"2012","unstructured":"Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X (2012) Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 35:15\u201336. doi:\n10.1111\/j.1365-2036.2011.04905.x","journal-title":"Aliment Pharmacol Ther"},{"key":"3554_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/MIB.0000000000000197","volume":"21","author":"J Amin","year":"2015","unstructured":"Amin J, Huang B, Yoon J, Shih DQ (2015) Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD. Inflamm Bowel Dis 21:445\u2013452. doi:\n10.1097\/MIB.0000000000000197","journal-title":"Inflamm Bowel Dis"},{"key":"3554_CR7","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1177\/1060028014521389","volume":"48","author":"M Dor\u00e9","year":"2014","unstructured":"Dor\u00e9 M, Frenette AJ, Mansour AM, Troyanov Y, B\u00e9gin J (2014) Febuxostat as a novel option to optimize thiopurines\u2019 metabolism in patients with inadequate metabolite levels. Ann Pharmacother 48:648\u2013651. doi:\n10.1177\/1060028014521389","journal-title":"Ann Pharmacother"},{"key":"3554_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.bcp.2013.06.002","volume":"86","author":"PA Blaker","year":"2013","unstructured":"Blaker PA, Arenas-Hernandez M, Smith M, Shobowale-Bakre EM, Fairbanks L, Irving PM et al (2013) Mechanism of allopurinol induced TPMT inhibition. Biochem Pharmacol 86:539\u2013547. doi:\n10.1016\/j.bcp.2013.06.002","journal-title":"Biochem Pharmacol"},{"key":"3554_CR9","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/ibd.21458","volume":"17","author":"ML Haines","year":"2011","unstructured":"Haines ML, Ajlouni Y, Irving PM, Sparrow MP, Rose R, Gearry RB et al (2011) Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 17:1301\u20131307. doi:\n10.1002\/ibd.21458","journal-title":"Inflamm Bowel Dis"},{"key":"3554_CR10","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00228-008-0478-6","volume":"64","author":"S Sahasranaman","year":"2008","unstructured":"Sahasranaman S, Howard D, Roy S (2008) Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 64:753\u2013767. doi:\n10.1007\/s00228-008-0478-6","journal-title":"Eur J Clin Pharmacol"},{"key":"3554_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1136\/gut.39.3.401","volume":"39","author":"C Cuffari","year":"1996","unstructured":"Cuffari C, Th\u00e9or\u00eat Y, Latour S, Seidman EG (1996) 6-mercaptopurine metabolism in Crohn\u2019s disease: correlation with efficacy and toxicity. Gut 39:401\u2013406. doi:\n10.1136\/gut.39.3.401","journal-title":"Gut"},{"key":"3554_CR12","first-page":"651","volume":"32","author":"RM Weinshilboum","year":"1980","unstructured":"Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651\u2013662","journal-title":"Am J Hum Genet"},{"key":"3554_CR13","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1111\/j.1572-0241.2008.01848.x","volume":"103","author":"JP Gisbert","year":"2008","unstructured":"Gisbert JP, Gomoll\u00f3n F (2008) Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 103:1783\u20131800. doi:\n10.1111\/j.1572-0241.2008.01848.x","journal-title":"Am J Gastroenterol"},{"key":"3554_CR14","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1111\/j.1572-0241.2006.00843.x","volume":"101","author":"JP Gisbert","year":"2006","unstructured":"Gisbert JP, Ni\u00f1o P, Rodrigo L, Cara C, Guijarro LG (2006) Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol 101:2769\u20132776. doi:\n10.1111\/j.1572-0241.2006.00843.x","journal-title":"Am J Gastroenterol"},{"key":"3554_CR15","first-page":"S30","volume":"3","author":"EG Seidman","year":"2003","unstructured":"Seidman EG (2003) Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 3:S30\u2013S38","journal-title":"Rev Gastroenterol Disord"},{"key":"3554_CR16","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1053\/j.gastro.2004.09.061","volume":"127","author":"GR Lichtenstein","year":"2004","unstructured":"Lichtenstein GR (2004) Use of laboratory testing to guide 6-mercaptopurine\/azathioprine therapy. Gastroenterology 127:1558\u20131564. doi:\n10.1053\/j.gastro.2004.09.061","journal-title":"Gastroenterology"},{"key":"3554_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/ijcp.12039","volume":"67","author":"M Smith","year":"2013","unstructured":"Smith M, Blaker P, Patel C, Marinaki A, Arenas M, Escuredo E et al (2013) The impact of introducting thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Int J Clin Pract 67:161\u2013169. doi:\n10.1111\/ijcp.12039","journal-title":"Int J Clin Pract"},{"key":"3554_CR18","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1053\/gg.2000.5925","volume":"118","author":"MC Dubinski","year":"2000","unstructured":"Dubinski MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Th\u00e9or\u00eat Y et al (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118:705\u2013713. doi:\n10.1053\/gg.2000.5925","journal-title":"Gastroenterology"},{"key":"3554_CR19","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1053\/j.gastro.2006.01.046","volume":"130","author":"MT Osterman","year":"2006","unstructured":"Osterman MT, Kundu R, Lichtenstein GR, Lewis JD (2006) Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130:1047\u20131053. doi:\n10.1053\/j.gastro.2006.01.046","journal-title":"Gastroenterology"},{"key":"3554_CR20","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.crohns.2011.12.003","volume":"6","author":"LPL Gilissen","year":"2012","unstructured":"Gilissen LPL, Wong DR, Engels LGJB, Bierau J, Bakker JA, Paulussen ADC et al (2012) Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. J Crohns Colitis 6:698\u2013707. doi:\n10.1016\/j.crohns.2011.12.003","journal-title":"J Crohns Colitis"},{"key":"3554_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/01.MIB.0000439068.71126.00","volume":"20","author":"AC Moreau","year":"2014","unstructured":"Moreau AC, Paul S, Tedesco ED, Rinaudo-Gaujous M, Boukhadra N, Genin C et al (2014) Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis. Inflamm Bowel Dis 20:464\u2013471. doi:\n10.1097\/01.MIB.0000439068.71126.00","journal-title":"Inflamm Bowel Dis"},{"key":"3554_CR22","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/hep.25760","volume":"56","author":"HK Dhaliwal","year":"2012","unstructured":"Dhaliwal HK, Anderson R, Thornhill EL, Schneider S, Mcfarlane E, Gleeson D et al (2012) Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. Hepatology 56:1401\u20131408. doi:\n10.1002\/hep.25760","journal-title":"Hepatology"},{"key":"3554_CR23","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/j.1400-1746.2005.03832.x","volume":"20","author":"RB Gearry","year":"2005","unstructured":"Gearry RB, Barclay ML (2005) Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 20:1149\u20131157. doi:\n10.1111\/j.1400-1746.2005.03832.x","journal-title":"J Gastroenterol Hepatol"},{"key":"3554_CR24","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1053\/gast.2002.32420","volume":"122","author":"MC Dubinski","year":"2002","unstructured":"Dubinski MC, Yang HY, Hassard PV, Seidman EG, Kam LY, Abreu MT et al (2002) 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122:904\u2013915. doi:\n10.1053\/gast.2002.32420","journal-title":"Gastroenterology"},{"key":"3554_CR25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S1542-3565(04)00127-2","volume":"2","author":"C Cuffari","year":"2004","unstructured":"Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM (2004) Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2:410\u2013417","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3554_CR26","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1046\/j.0269-2813.2002.01353.x","volume":"16","author":"A Ansari","year":"2002","unstructured":"Ansari A, Hassan C, Dudley J, Marinaki A, Shobowale-Bakre EM, Seed P et al (2002) Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 16:1743\u20131750. doi:\n10.1046\/j.0269-2813.2002.01353.x","journal-title":"Aliment Pharmacol Ther"},{"key":"3554_CR27","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/j.1365-2036.2012.05084.x","volume":"35","author":"R Egmond van","year":"2012","unstructured":"van Egmond R, Chin P, Zhang M, Sies CW, Barclay ML (2012) High TPMT enzyme activity does not explain drug resistance due to preferential 6-mercaptopurine production in patients on thiopurine treatment. Aliment Pharmacol Ther 35:1181\u20131189. doi:\n10.1111\/j.1365-2036.2012.05084.x","journal-title":"Aliment Pharmacol Ther"},{"key":"3554_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cgh.2006.11.020","volume":"5","author":"MP Sparrow","year":"2007","unstructured":"Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB (2007) Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 5:209\u2013214. doi:\n10.1016\/j.cgh.2006.11.020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3554_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1440-1746.2010.06489.x","volume":"26","author":"SJ Gardiner","year":"2011","unstructured":"Gardiner SJ, Gearry RB, Burt MJ, Chalmers-Watson T, Chapman BA, Ross AG et al (2011) Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. J Gastroenterol Hepatol 26:49\u201354. doi:\n10.1111\/j.1440-1746.2010.06489.x","journal-title":"J Gastroenterol Hepatol"},{"key":"3554_CR30","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.crohns.2012.12.006","volume":"7","author":"ML Seinen","year":"2013","unstructured":"Seinen ML, van Asseldonk DP, de Boer NKH, Losekoot N, Smid K, Mulder CJJ et al (2013) The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results form a prospective pharmacological study. J Crohns Colitis 7:812\u2013819. doi:\n10.1016\/j.crohns.2012.12.006","journal-title":"J Crohns Colitis"},{"key":"3554_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3899\/jrheum.070968","volume":"36","author":"AD Askanase","year":"2009","unstructured":"Askanase AD, Wallace DJ, Weisman MH, Tseng CE, Bernstein L, Belmont HM et al (2009) Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. J Rheumatol 36:89\u201395. doi:\n10.3899\/jrheum.070968","journal-title":"J Rheumatol"},{"key":"3554_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jchromb.2003.09.017","volume":"798","author":"LT Ford","year":"2003","unstructured":"Ford LT, Berg JD (2003) Determination of thiopurine S-methyltransferase activity in erythrocytes using 6-thioguanine as substrate and a non-extraction liquid chromatographic technic. J Chromatogr 798:111\u2013115. doi:\n10.1016\/j.jchromb.2003.09.017","journal-title":"J Chromatogr"},{"key":"3554_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1258\/0004563041201617","volume":"41","author":"LT Ford","year":"2004","unstructured":"Ford LT, Cooper SC, Lewis MJ, Berg JD (2004) Reference intervals for thiopurine S-methyltransferase activity in red blood cells using 6-thioguanine as substrate and rapid non-extraction liquid chromatography. Ann Clin Biochem 41:303\u2013308. doi:\n10.1258\/0004563041201617","journal-title":"Ann Clin Biochem"},{"key":"3554_CR34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0378-4347(92)80347-S","volume":"583","author":"L Lennard","year":"1992","unstructured":"Lennard L, Singleton HJ (1992) High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 583:83\u201390","journal-title":"J Chromatogr"},{"key":"3554_CR35","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.crohns.2012.02.007","volume":"6","author":"MA Smith","year":"2012","unstructured":"Smith MA, Blaker P, Marikani AM, Anderson SH, Irving PM, Sanderson JD (2012) Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis 6:905\u2013912. doi:\n10.1016\/j.crohns.2012.02.007","journal-title":"J Crohns Colitis"},{"key":"3554_CR36","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1111\/j.1572-0241.2005.41900.x","volume":"100","author":"MC Dubinski","year":"2005","unstructured":"Dubinski MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ (2005) A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn\u2019s disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 100:2239\u20132247. doi:\n10.1111\/j.1572-0241.2005.41900.x","journal-title":"Am J Gastroenterol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3554-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3554-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3554-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T01:06:21Z","timestamp":1496365581000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3554-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,27]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["3554"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3554-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,27]]}}}